RESULTS
Pulmonary Infection, pneumonia, XDR, nephrotoxicity
PNEUMONIA, DISEASES
In this research, 60 individuals with XDR The study's CONSORT flowchart.In terms of age and gender distribution, the reason for ICU admission, underlying diseases, latest antibiotic consumption, and past ICU admission history, the two groups did not significantly differ (Table Distribution of demographic characteristics and clinical history of subjects in the groups.Gender
Abbreviations: ICU, intensive care unit; VAP, ventilator‐associated pneumonia.The mean CPIS did not differ between the groups at the start of treatment; however, at 72 h treated with tobramycin/fosfomycin, 7 days later, and at the treatment termination, the mean score in the tobramycin/fosfomycin group was significantly lower. Also, in intragroup examinations, the CPIS in both groups was significantly reduced (CPIS changes trend during treatment among the groups. CPIS, Clinical Pulmonary Infection Score.Mean and standard deviation of Clinical Pulmonary Infection Score over the treatment period of the groups.Significant level of difference among the groups in each time period according to the Significant level of difference within each group on the basis of repeated measures ANOVA.Significant level of difference between the two groups based on repeated measures ANOVA.According to the results, the mean levels of C‐reactive protein (CRP) and procalcitonin in the treatment dimension in both groups were significantly reduced compared with the beginning of treatment; however, their changes trend did not significantly differ between the groups. Mean creatinine and urea levels at the beginning and end of the study did not significantly differ among the groups (Table Mean and standard deviation of serum procalcitonin, urea, and creatinine levels in the two groups.Significant level of difference among the groups in each time period based on independent sample Significant level of difference within each group based on paired sample Significant level of difference between the two groups based on repeated measures ANOVA.Endotracheal aspiration (ETA) culture results 7 days after the treatment initiation were negative in nine patients (32.1%) of the inhaled colistin group and in 25 patients (92.6%) of the inhaled tobramycin/fosfomycin group, and the difference among the groups was significant (The mean duration of treatment was 13.73 ± 3.22 days in the colistin group and 10.85 ± 2.84 days in the tobramycin/fosfomycin group, and the mean treatment duration in the inhaled fosfomycin/tobramycin group significantly was lower (Two (6.67%) patients in the control group and three (10%) patients in the case group died. In terms of medicine side effects, 11 subjects (39.3%) in the control group and five subjects (18.5%) in the case group exhibited nephrotoxicity symptoms, although the difference was not statistically significant (